Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

Affiliations

• ¹ Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. msekeres@med.miami.edu.
• ² Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
• ³ University Hospital Sveti Ivan Rislki, Sofia, Bulgaria.
• ⁴ Institut Català d'Oncologia-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospitalet, Barcelona, Spain.
• ⁵ Department of Molecular Biotechnology and Health Sciences, Division of Hematology, University of Turin, Turin, Italy.
• ⁶ Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
• ⁷ University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
• ⁸ University Hospital of Salamanca, IBSAL Institute for Biomedical Research of Salamanca, Salamanca, Spain.
• ⁹ Department of Hematology, Université Catholique de Louvain, CHU UCL Namur (Godinne site), Yvoir, Belgium.
• ¹⁰ The James P Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA.
• ¹¹ AZ Sint Jan Brugge-Oostende, Brugge, Belgium.
• ¹² MHAT Dr. Georgi Stranski, Clinic of Haematology, Pleven, Bulgaria.
• ¹³ Millennium Pharmaceuticals, Inc. a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
• ¹⁴ AP-HP, Hôpital Saint Louis, Paris, France.
• ¹⁵ University of Paris, and INSERM U944, Paris, France.